CJC-1295 (No DAC) + Ipamorelin is a dual–peptide research compound studied for its interaction with growth hormone regulatory pathways, combining a growth hormone–releasing hormone (GHRH) analog with a ghrelin receptor agonist. This combination is investigated in experimental models for its ability to influence pulsatile growth hormone secretion through complementary receptor mechanisms. Research has explored its effects on pituitary signaling, insulin–like growth factor–1 (IGF–1) pathways, and endocrine system modulation under controlled laboratory conditions. The GHRH component supports stimulation of growth hormone release, while Ipamorelin selectively targets ghrelin receptors to enhance signaling specificity. Additional studies evaluate receptor binding dynamics, signaling cascade activation, and hormonal response patterns across research models. Its combined structure allows for coordinated pathway interaction and sustained signaling behavior in experimental environments. Ongoing investigations continue to examine its biochemical properties and regulatory effects within the hypothalamic–pituitary axis.